Press release
Myelodysplastic Syndrome Pipeline Outlook Report 2024 (Updated)
Myelodysplastic Syndrome Pipeline
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome pipeline report depicts a robust space with 120+ active players working to develop 150+ pipeline therapies for Myelodysplastic Syndrome treatment.
• The leading companies working in the Myelodysplastic Syndrome Market include Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
• Promising Myelodysplastic Syndrome Pipeline Therapies in the various stages of development include Venetoclax, Azacitidine, Luspatercept, Epoetin alfa, FG-4592, Lenalidomide 5 mg, and others.
• March 2024: AbbVie announced a study of Phase 3 clinical trials for Venetoclax and Azacitidine. Myelodysplastic Syndrome (MDS) is a group of disorders that gradually affect the ability of a person's bone marrow (semi-liquid tissue present in many bones like backbones) to produce normal blood cells. Some people with MDS have a risk of the disease progressing to acute myeloid leukemia (AML), and a risk of death from the disease itself.
• March 2024: Agios Pharmaceuticals Inc. announced a study of Phase 2 clinical trials for AG-946. This purpose of this study is to establish proof of concept of AG-946 in participants with LR-MDS in Phase 2a and to compare the effect of AG-946 versus placebo and to detect a dose response for erythroid response in participants with LR-MDS in Phase 2b.
• December 2023: Celgene announced a study of Phase 3 clinical trials for Luspatercept and Epoetin Alfa. The purpose of this study is to determine the effectiveness of luspatercept (ACE-536) compared to epoetin alfa on red blood cell (RBC) transfusion independence (for at least 12 weeks) with a concurrent hemoglobin increase of at least 1.5 g/dL in participants with anemia due to revised international prognostic scoring system (IPSS-R) very low, low, or intermediate risk myelodysplastic syndromes (MDS) who require RBC transfusions and have never been exposed to erythropoiesis stimulating agent (ESA).
• December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Luspatercept and Epoetin Alfa. The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
• December 2023: Celgene announced a study of Phase 1 clinical trials for CC-91633. Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The Dose Escalation part (Part A) of the study will enroll participants with R/R AML and R/R HR-MDS and will evaluate the safety and tolerability of escalating doses of CC-91633 (BMS-986397), administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 dose (RP2D) and schedule.
Request a sample and discover the recent advances in Myelodysplastic Syndrome Treatment Drugs @ Myelodysplastic Syndrome Pipeline Outlook Report- https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Myelodysplastic Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myelodysplastic Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Myelodysplastic Syndrome Overview
Myelodysplastic syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow. Some patients with MDS may have a transformation into acute myeloid leukemia (AML). MDS is usually diagnosed in older patients over the age of 65. Clinical manifestations include a decrease in the number of red blood cells (RBC), platelets, and white blood cells (WBC). The disease course is variable.
Find out more about Myelodysplastic Syndrome Treatment Landscape @ Drugs for Myelodysplastic Syndrome Treatment- https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Myelodysplastic Syndrome Emerging Drugs Profile
• MBG453: Novartis
• Tamibarotene: Syros Pharmaceuticals
• CA-4948: Curis
• RVU120: Ryvu Therapeutics
Myelodysplastic Syndrome Pipeline Therapeutics Assessment
There are approx. 120+ key companies which are developing the therapies for Myelodysplastic Syndrome. The Myelodysplastic Syndrome companies which have their Myelodysplastic Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Novartis.
DelveInsight's Myelodysplastic Syndrome Pipeline Report covers around 150+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Myelodysplastic Syndrome Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Learn more about the emerging Myelodysplastic Syndrome Pipeline Therapies @ Myelodysplastic Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Myelodysplastic Syndrome Pipeline Report
• Coverage- Global
• Myelodysplastic Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Myelodysplastic Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Myelodysplastic Syndrome Companies- Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
• Myelodysplastic Syndrome Pipeline Therapies- Venetoclax, Azacitidine, Luspatercept, Epoetin alfa, FG-4592, Lenalidomide 5 mg, and others.
Dive deep into rich insights for new drugs for Myelodysplastic Syndrome treatment, Visit @ Myelodysplastic Syndrome Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Myelodysplastic Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Myelodysplastic Syndrome- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. MBG453: Novartis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CA-4948: Curis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RVU120: Ryvu Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Myelodysplastic Syndrome Key Companies
21. Myelodysplastic Syndrome Key Products
22. Myelodysplastic Syndrome- Unmet Needs
23. Myelodysplastic Syndrome- Market Drivers and Barriers
24. Myelodysplastic Syndrome- Future Perspectives and Conclusion
25. Myelodysplastic Syndrome Analyst Views
26. Myelodysplastic Syndrome Key Companies
27. Appendix
For further information on the Myelodysplastic Syndrome Pipeline Therapeutics, reach out @ Myelodysplastic Syndrome Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://theventurecation.com/author/germanydennydones/
https://blogstudiio.com/fabry-disease-market-size/
https://meccapost.com/author/germanydennydones/
https://kitmaker.net/profile/yashveer-bhardwaj
http://www.costaricajobsearch.com/author/germanydennydones/
https://keralaclick.com/classified-advertising/user/profile/182882
https://aviator.forex.pm/?qa=user/germanydennydones
https://careers.coloradopublichealth.org/employers/2926283-delveinsight
https://www.heavyironjobs.com/profiles/4448319-denny-dones
https://jobs.blooloop.com/employers/2614577-delveinsight
https://www.animaljobsdirect.com/employers/2926436-delveinsight
https://jobs.windomnews.com/employers/2926467-delveinsight
https://jobs.fsoma.org/employers/2926471-delveinsight
https://jobs.thetab.com/employers/1458246-delveinsight
https://forum.squarespace.com/profile/421527-dennydonesgermany/?tab=field_core_pfield_1
https://camp-fire.jp/profile/germanydennydones
https://myaajkal.xyz/page/other/atopic-dermatitis-market-size/
https://talkotive.com/read-blog/136659
https://monstaluck.mn.co/posts/53508338
https://network-6063768.mn.co/posts/53508913
https://black-gun-association.mn.co/posts/53509422
https://charleston-wiffleball-association.mn.co/posts/53509543
https://network-6247558.mn.co/posts/53509666
https://franko-trading-enterprise.mn.co/posts/53509819
https://nordic-future.mn.co/posts/53509979
https://the-trifecta-network.mn.co/posts/53510053
https://diamond-members.mn.co/posts/53510731
https://tonow.mn.co/posts/53510860
https://network-1062788.mn.co/posts/53511032
https://d6united.mn.co/posts/53511102
https://mighty-networks-foundation.mn.co/posts/53511176
https://network-759413.mn.co/posts/53511779
https://walkinvirtualclinics.mn.co/posts/53511912
https://inbound-tourism-inner-circle.mn.co/posts/53512259
https://acertdglobalplatform.mn.co/posts/53512375
https://comidarealkitchen.mn.co/posts/53512492
https://ripple-xrp-global-network.mn.co/posts/understanding-the-atopic-dermatitis-market-size-forecast-and-outlook
https://facial546.mn.co/posts/53513294
https://moneyschoolinc.mn.co/posts/53513378
https://mylook-online.mn.co/posts/53513464
https://network-6063768.mn.co/posts/53513575
https://edpt200.mn.co/posts/53513922
https://decorated-with-members.mn.co/posts/53514022
https://fromfostercaretoceo.mn.co/posts/53514116
https://foodxtech.mn.co/posts/53514153
https://thinktrain.mn.co/posts/53514300
https://nc-cricket.mn.co/posts/53514349
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myelodysplastic Syndrome Pipeline Outlook Report 2024 (Updated) here
News-ID: 3444249 • Views: …
More Releases from DelveInsight Business Research LLP
Atopic Dermatitis Clinical, Companies, Therapeutic Assessment, Therapies, Treatm …
Atopic Dermatitis Pipeline constitutes 100+ key companies continuously working towards developing 120+ Atopic Dermatitis treatment therapies, analyzes DelveInsight.
Atopic Dermatitis Overview:
Atopic Dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition and the most prevalent form of skin inflammation. While it often begins in early childhood, it can occur at any age and may be recurrent or persist throughout life. The term "dermatitis" comes from "derm" meaning skin and…
Electrical Stimulation Devices Market Poised for Steady Growth, Fueled by Innova …
The global functional electrical stimulation (FES) devices market is projected to grow at a CAGR of 8.2% from 2024 to 2030. Growth is mainly driven by the increasing prevalence of musculoskeletal disorders worldwide, along with the growing emphasis on pain management therapies and continuous technological advancements in product development, which are expected to further boost the market in the coming years.
DelveInsight's Electrical Stimulation Devices Market Insights report provides the current…
Brain Monitoring Devices Market Poised for Steady Growth, Fueled by Innovation a …
The brain monitoring devices market, valued at USD 5.89 billion in 2023, is projected to grow at a CAGR of 7.27% from 2024 to 2030, reaching USD 9.13 billion by 2030. Growth is driven by the rising prevalence of neurological disorders such as multiple sclerosis, epilepsy, and dementia, along with increasing awareness and ongoing product development activities, all contributing to the market's expansion during the forecast period.
DelveInsight's Brain Monitoring Devices…
Sleep Apnea Devices Market Poised for Steady Growth, Fueled by Innovation and Ri …
The global sleep apnea devices market, valued at USD 7.53 billion in 2023, is projected to grow at a CAGR of 6.26% from 2024 to 2030, reaching USD 10.82 billion by 2030. Growth is driven by the rising prevalence of sleep apnea, increasing obesity rates, and greater adoption of advanced technologies. Additional factors such as heightened awareness, a growing elderly population, and a surge in product launches and approvals are…
More Releases for Myelodysplastic
Myelodysplastic Syndrome Drugs Market Research and Treatment Advancements
On April 11, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Myelodysplastic Syndrome Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands…
Prominent Myelodysplastic Syndrome (MDS) Drugs Market Trend for 2025: Innovative …
What Are the Projected Growth and Market Size Trends for the Myelodysplastic Syndrome (MDS) Drugs Market?
The myelodysplastic syndrome (MDS) drugs market has expanded steadily in recent years. It is projected to increase from $3.47 billion in 2024 to $3.73 billion in 2025, reflecting a CAGR of 7.5%. The past growth can be attributed to the aging population, advancements in targeted therapies, ongoing clinical trials, and increased awareness.
The myelodysplastic syndrome (MDS)…
Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast to 2031
"Myelodysplastic Syndrome (MDS) Treatment Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Myelodysplastic Syndrome (MDS) Treatment market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Myelodysplastic Syndrome (MDS) Treatment industry, providing stakeholders…
Myelodysplastic Syndrome Market Size, Epidemiology, Analysis & Trends 2023-2033
Market Overview:
The myelodysplastic syndrome market is expected to exhibit a CAGR of 6.51% during 2023-2033. The myelodysplastic syndrome market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the…
Myelodysplastic Syndrome Market to see Huge Growth by 2029
Myelodysplastic Syndrome Market was valued at USD 2.8 billion in 2022 and is expected to grow at a CAGR of 10% between 2023 and 2029. Important changes in the business allow key players to attain larger profits. This Myelodysplastic Syndrome Market study report is the best way to make changes with the help of entire market condition and metrics provided here. These metrics also allow getting ahead in the industry.…
Myelodysplastic Syndrome Market Global Research and Clinical Analysis 2020
Global Myelodysplastic Syndrome Market research report published by market insight reports explores the current outlook in global and key regions from the perspective of Major Players, Countries, Product types and end industries. This report analyzes top players in the global market, and divides the Market into several parameters.
This Myelodysplastic Syndrome Market research report identifies the competitive landscape of industries to understand the competition at International level. This report study describes…
